Skip to content
Back to meeting Original
Mirrors of Medicine路 @mirrorsmed 路 X路路 20 hours agoScore70

LITESPARK-012

Body

馃敶 Presented at #ESMO26 | LITESPARK-012 in advanced ccRCC
Does adding more to an established 1L combination improve outcomes?
鉃★笍 Adding belzutifan to pembrolizumab + lenvatinib did not improve PFS or OS
鉃★笍 Adding CTLA-4 blockade (quavonlimab) also did not improve efficacy
鉃★笍 Discontinuations due to AEs were higher with both investigational regimens
鉃★笍 Clinical takeaway: pembrolizumab + lenvatinib remains a standard 1L option in advanced ccRCC
#KidneyCancer #RCC #ESMO2026

32 views 路 0 likes 路 1 repost 路 0 replies

Source: Mirrors of Medicine 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.